新西兰将从2026年4月1日起扩大获得cyctic fibrosis治疗的机会,没有年龄限制和更广泛的遗传资格。 New Zealand will expand cystic fibrosis treatment access starting April 1, 2026, with no age limits and broader genetic eligibility.

自2026年4月1日起,新西兰将扩大获得囊性纤维化治疗的机会,包括Trikafta、Kalydeco和Alyftrek,扩大基因突变资格范围,不限制资金年龄。 Starting April 1, 2026, New Zealand will expand access to cystic fibrosis treatments including Trikafta, Kalydeco, and Alyftrek, with broader eligibility for genetic mutations and no age restrictions for funding. 这项行动是在广泛征求公众意见的基础上进行的,目的是使早期治疗能够预防肺损伤,减少住院,提高生活质量。 The move, based on extensive public consultation, aims to enable earlier treatment to prevent lung damage, reduce hospitalizations, and improve quality of life. 虽然目前的医疗安全批准将Trikafta限制在2岁及以上,Alyftrek限制在6岁及以上,但现在将根据临床需要提供资金。 While current Medsafe approvals limit Trikafta to ages two and older and Alyftrek to six and older, funding will now be based on clinical need. 这些变化反映了为改善长期保健成果和减轻保健系统负担所作的努力。 The changes reflect efforts to improve long-term health outcomes and reduce strain on the healthcare system.